Arrowhead Pharmaceuticals, Inc.
82.63USD
-2.4800 (-2.91%)
Fetching financial statements from SEC filings…
| In $M except per-share | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25* | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24* |
|---|---|---|---|---|---|---|---|---|
| Revenue | 75 | 74 | 264 | 256 | 28 | 543 | 3 | 0 |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Operating Income | -170 | -141 | 41 | 44 | -166 | 381 | -161 | -162 |
| Net Income | -194 | -133 | 31 | -24 | -175 | 370 | -173 | -171 |
| EPS (Diluted) | $-1.36 | $-0.93 | $0.22 | $-0.18 | $-1.26 | $2.75 | $-1.39 | $-1.37 |
* Derived period (computed from FY minus reported quarters). Source: SEC filings (EDGAR)